Rebiotix Inc., a Ferring Company
Rebiotix Inc., a Ferring Company, is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome. The company is on the forefront of an exciting potential medical breakthrough with our MRT drug platform. The MRT drug platform is leveraged to develop formulations consisting of live microbes, which are evaluated through our clinical program for the formulation’s ability to address challenging diseases. We have the most advanced human clinical program with extensive clinical trial experience in multiple indications, evaluating an investigative microbiota-based live biotherapeutic drug.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2011
- Employees:
- 11-100
About us
Driven to help people live better lives
Through strong science and careful clinical evaluation, we aim to develop microbiota-based live biotherapeutics that bring the potential of the human microbiome to the patients and physicians who need them most.
In 2018, Rebiotix joined Ferring Pharmaceuticals, a globally-recognized specialty pharmaceutical company driven to help people live better lives. Combined with their history and passion for microbiome-based research, our ability to make microbiota-based live biotherapeutics may soon be a reality.
The Leader in Developing Microbiota-Based Therapies through the MRT™ Drug Platform
The MRT platform is our technology for developing formulations consisting of live, human-derived microbes.
We have the most advanced human clinical program with extensive clinical trial experience in multiple indications, evaluating an investigative microbiota-based live biotherapeutic drug. Our research, conducted in coordination with regulatory authorities, encompasses studies with acute and chronic disease states through both company- and physician-sponsored trials. Check out our clinical program, including our advanced investigative programs for recurrent Clostridioides difficile infection, for more information.